OBJECTIVES: Long-term follow-up study to evaluate the impact on disease-free survival and cancer-specific survival of survivin expression in tissue and CTCs from T1G3 bladder cancer patients. PATIENTS AND METHODS: The study was conducted using tumor tissue and blood samples from 54 patients with a primary diagnosis of T1G3 NMIBC. Survivin was evaluated by reverse transcription-polymerase chain reaction in tumor tissues. CTCs were isolated from blood by CELLection™ Dynabeads (Invitrogen, Carlsbad, CA, USA). Cells were lysed and cDNA was synthesized and analysed for the expression of CD45, CK8 and survivin. The endpoints of this long-termanalysis were disease-free survival, DFS and cancer-specific survival, CSS. RESULTS: Here, we report that, at 9 years of median follow-up, disease-free survival and cancer-specific survival are both significantly influenced by the expression of survivin in tumor tissue (p = 0.006), by the presence of CTCs (p < 0.0001) and by the expression of survivin in CTCs (p < 0.0001). CONCLUSION: The statistically significant impact of survivin expressing CTCs on cancer-specific survival that we observed might be interpreted as the result of the persistence of a subpopulation of highlander cells in the blood of T1G3 bladder patients over time.

The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC) / Nicolazzo, Chiara; Busetto, GIAN MARIA; DEL GIUDICE, Francesco; Sperduti, Isabella; Giannarelli, Diana; Gradilone, Angela; Gazzaniga, Paola; DE BERARDINIS, Ettore; Raimondi, Cristina. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - STAMPA. - 143:10(2017), pp. 1971-1976. [10.1007/s00432-017-2449-8]

The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)

NICOLAZZO, CHIARA;BUSETTO, GIAN MARIA;DEL GIUDICE, FRANCESCO;SPERDUTI, ISABELLA;GRADILONE, Angela;GAZZANIGA, PAOLA;DE BERARDINIS, Ettore;RAIMONDI, CRISTINA
2017

Abstract

OBJECTIVES: Long-term follow-up study to evaluate the impact on disease-free survival and cancer-specific survival of survivin expression in tissue and CTCs from T1G3 bladder cancer patients. PATIENTS AND METHODS: The study was conducted using tumor tissue and blood samples from 54 patients with a primary diagnosis of T1G3 NMIBC. Survivin was evaluated by reverse transcription-polymerase chain reaction in tumor tissues. CTCs were isolated from blood by CELLection™ Dynabeads (Invitrogen, Carlsbad, CA, USA). Cells were lysed and cDNA was synthesized and analysed for the expression of CD45, CK8 and survivin. The endpoints of this long-termanalysis were disease-free survival, DFS and cancer-specific survival, CSS. RESULTS: Here, we report that, at 9 years of median follow-up, disease-free survival and cancer-specific survival are both significantly influenced by the expression of survivin in tumor tissue (p = 0.006), by the presence of CTCs (p < 0.0001) and by the expression of survivin in CTCs (p < 0.0001). CONCLUSION: The statistically significant impact of survivin expressing CTCs on cancer-specific survival that we observed might be interpreted as the result of the persistence of a subpopulation of highlander cells in the blood of T1G3 bladder patients over time.
2017
Circulating tumor cells; Non-muscle invasive bladder cancer; Prognosis; Survivin; T1G3 bladder cancer; Oncology; Cancer Research
01 Pubblicazione su rivista::01a Articolo in rivista
The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC) / Nicolazzo, Chiara; Busetto, GIAN MARIA; DEL GIUDICE, Francesco; Sperduti, Isabella; Giannarelli, Diana; Gradilone, Angela; Gazzaniga, Paola; DE BERARDINIS, Ettore; Raimondi, Cristina. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - STAMPA. - 143:10(2017), pp. 1971-1976. [10.1007/s00432-017-2449-8]
File allegati a questo prodotto
File Dimensione Formato  
Nicolazzo_long‑term-prognostic_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 569.33 kB
Formato Adobe PDF
569.33 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1012617
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 38
social impact